CMXHF
Price
$125.40
Change
-$11.22 (-8.21%)
Updated
Sep 23 closing price
Capitalization
63.91B
REGN
Price
$576.91
Change
+$9.02 (+1.59%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
60.19B
36 days until earnings call
Interact to see
Advertisement

CMXHF vs REGN

Header iconCMXHF vs REGN Comparison
Open Charts CMXHF vs REGNBanner chart's image
CSL
Price$125.40
Change-$11.22 (-8.21%)
Volume$875
Capitalization63.91B
Regeneron Pharmaceuticals
Price$576.91
Change+$9.02 (+1.59%)
Volume$9.3K
Capitalization60.19B
CMXHF vs REGN Comparison Chart in %
Loading...
CMXHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMXHF vs. REGN commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMXHF is a Hold and REGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (CMXHF: $125.40 vs. REGN: $567.89)
Brand notoriety: CMXHF: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMXHF: 138% vs. REGN: 136%
Market capitalization -- CMXHF: $63.91B vs. REGN: $60.19B
CMXHF [@Biotechnology] is valued at $63.91B. REGN’s [@Biotechnology] market capitalization is $60.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMXHF’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • CMXHF’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than CMXHF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMXHF’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).

  • CMXHF’s TA Score: 5 bullish, 5 bearish.
  • REGN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, REGN is a better buy in the short-term than CMXHF.

Price Growth

CMXHF (@Biotechnology) experienced а -6.58% price change this week, while REGN (@Biotechnology) price change was -1.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CMXHF($63.9B) has a higher market cap than REGN($60.2B). CMXHF has higher P/E ratio than REGN: CMXHF (20.32) vs REGN (14.31). REGN YTD gains are higher at: -19.935 vs. CMXHF (-24.399). REGN has higher annual earnings (EBITDA): 5.42B vs. CMXHF (5.13B). REGN has more cash in the bank: 7.47B vs. CMXHF (1.52B). REGN has less debt than CMXHF: REGN (2.71B) vs CMXHF (12B). CMXHF has higher revenues than REGN: CMXHF (15.4B) vs REGN (14.2B).
CMXHFREGNCMXHF / REGN
Capitalization63.9B60.2B106%
EBITDA5.13B5.42B95%
Gain YTD-24.399-19.935122%
P/E Ratio20.3214.31142%
Revenue15.4B14.2B108%
Total Cash1.52B7.47B20%
Total Debt12B2.71B444%
FUNDAMENTALS RATINGS
CMXHF vs REGN: Fundamental Ratings
CMXHF
REGN
OUTLOOK RATING
1..100
875
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9754
PRICE GROWTH RATING
1..100
8361
P/E GROWTH RATING
1..100
9195
SEASONALITY SCORE
1..100
6543

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CMXHF's Valuation (2) in the null industry is in the same range as REGN (3) in the Biotechnology industry. This means that CMXHF’s stock grew similarly to REGN’s over the last 12 months.

CMXHF's Profit vs Risk Rating (100) in the null industry is in the same range as REGN (100) in the Biotechnology industry. This means that CMXHF’s stock grew similarly to REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for CMXHF (97) in the null industry. This means that REGN’s stock grew somewhat faster than CMXHF’s over the last 12 months.

REGN's Price Growth Rating (61) in the Biotechnology industry is in the same range as CMXHF (83) in the null industry. This means that REGN’s stock grew similarly to CMXHF’s over the last 12 months.

CMXHF's P/E Growth Rating (91) in the null industry is in the same range as REGN (95) in the Biotechnology industry. This means that CMXHF’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMXHFREGN
RSI
ODDS (%)
Bullish Trend 2 days ago
55%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
55%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
57%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 8 days ago
48%
Bullish Trend 7 days ago
63%
Declines
ODDS (%)
Bearish Trend 6 days ago
48%
Bearish Trend 16 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
57%
Aroon
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
CMXHF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XLV136.940.31
+0.23%
The Health Care Select Sector SPDR® ETF
DSTX30.31N/A
N/A
Distillate Intntnl Fndmntl Stblty&Vl ETF
PGHY20.08-0.09
-0.45%
Invesco Glb ex-US High Yld Corp Bd ETF
AVES57.32-0.39
-0.68%
Avantis Emerging Markets Value ETF
CEPI39.99-1.64
-3.94%
Rex Crypto Equity Premium Income ETF

CMXHF and

Correlation & Price change

A.I.dvisor tells us that CMXHF and CCCC have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMXHF and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMXHF
1D Price
Change %
CMXHF100%
-8.21%
CCCC - CMXHF
26%
Poorly correlated
-0.77%
REGN - CMXHF
23%
Poorly correlated
-4.67%
NRIX - CMXHF
22%
Poorly correlated
-2.25%
GBIO - CMXHF
22%
Poorly correlated
-0.86%
VRDN - CMXHF
22%
Poorly correlated
+0.05%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with BMRN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-4.67%
BMRN - REGN
44%
Loosely correlated
-0.98%
ROIV - REGN
42%
Loosely correlated
-1.34%
SMMT - REGN
41%
Loosely correlated
+0.26%
ACLX - REGN
40%
Loosely correlated
+1.19%
TECH - REGN
39%
Loosely correlated
-0.23%
More